Jocelyn S. Penington

Parkville, NSW 3052, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Deconvolution of the On-Target Activity of Plasmepsin V Peptidomimetics in Plasmodium falciparum Parasites.

Deconvolution of the On-Target Activity of Plasmepsin V Peptidomimetics in Plasmodium falciparum Parasites.

Journal: ACS infectious diseases
Published: December 02, 2025

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma.

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma.

Journal: Journal of experimental & clinical cancer research : CR
Published: September 10, 2025

Exploration and Characterization of the Antimalarial Activity of Pyrimidine-2,4-Diamines for which Resistance is Mediated by the ABCI3 Transporter.

Exploration and Characterization of the Antimalarial Activity of Pyrimidine-2,4-Diamines for which Resistance is Mediated by the ABCI3 Transporter.

Journal: ChemMedChem
Published: August 29, 2025

MK-7602: a potent multi-stage dual-targeting antimalarial.

MK-7602: a potent multi-stage dual-targeting antimalarial.

Journal: EBioMedicine
Published: June 23, 2025

Optimization and Characterization of N-Acetamide Indoles as Antimalarials That Target PfATP4.

Optimization and Characterization of N-Acetamide Indoles as Antimalarials That Target PfATP4.

Journal: Journal of medicinal chemistry
Published: April 14, 2025

Exploration and characterization of the antimalarial activity of cyclopropyl carboxamides that target the mitochondrial protein, cytochrome b.

Exploration and characterization of the antimalarial activity of cyclopropyl carboxamides that target the mitochondrial protein, cytochrome b.

Journal: European journal of medicinal chemistry
Published: September 03, 2024

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

Journal: Molecular cancer
Published: May 23, 2024

A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review.

A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review.

Journal: Cancers
Published: July 27, 2023

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.

Journal: Therapeutic advances in medical oncology
Published: July 01, 2023

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

Journal: medRxiv : the preprint server for health sciences
Published: March 30, 2023

7-N-Substituted-3-oxadiazole Quinolones with Potent Antimalarial Activity Target the Cytochrome bc1 Complex.

7-N-Substituted-3-oxadiazole Quinolones with Potent Antimalarial Activity Target the Cytochrome bc1 Complex.

Journal: ACS infectious diseases
Published: February 28, 2023

Targeting homologous recombination deficiency in uterine leiomyosarcoma.

Targeting homologous recombination deficiency in uterine leiomyosarcoma.

Journal: Journal of experimental & clinical cancer research : CR
Published: February 14, 2023
Showing 1-12 of 22

Last Updated: 09/26/2026